Teleflex to sell OEM, acute care and urology units for $2.03 billion
Teleflex agreed on December 9, 2025 to sell its OEM business to Lotus US Bidco Inc., an affiliate of Montagu and Kohlberg, for $1.5 billion in cash, and its acute care and interventional urology segments to Intersurgical Limited for $530 million in cash. The company also authorized a share repurchase program of up to $1 billion, which it primarily plans to fund with the sale proceeds, while also intending to pay down debt. Closings are expected in the second half of 2026, subject to regulatory approvals and other conditions.
Key points
- OEM business sale to Lotus US Bidco Inc. for $1.5 billion in cash, with a $90 million termination fee payable by the buyer under certain circumstances
- Acute care and interventional urology segments sold to Intersurgical Limited for $530 million in cash
- Board authorized a share repurchase program of up to $1 billion; the company is not required to repurchase shares
- Both transactions expected to close in the second half of 2026; outside date September 1, 2026, with extensions possible
The filing
Written by AI on Nov 8, 2026, 12:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 09, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.